Brokerages Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) PT at $61.90

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have been given an average rating of “Hold” by the twelve brokerages that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, six have given a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $61.90.

Several brokerages have recently weighed in on HALO. Leerink Partnrs downgraded shares of Halozyme Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 13th. Wells Fargo & Company lifted their target price on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the company an “equal weight” rating in a report on Wednesday, May 7th. JPMorgan Chase & Co. lifted their target price on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a “neutral” rating in a report on Monday, April 21st. Benchmark downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 7th. Finally, Leerink Partners downgraded shares of Halozyme Therapeutics from a “market perform” rating to an “underperform” rating and set a $47.00 target price on the stock. in a report on Tuesday, May 13th.

Insider Buying and Selling

In related news, Director Jeffrey William Henderson sold 503 shares of the company’s stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total transaction of $32,217.15. Following the completion of the transaction, the director now owns 33,108 shares of the company’s stock, valued at approximately $2,120,567.40. This represents a 1.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Strs Ohio acquired a new position in Halozyme Therapeutics during the first quarter worth approximately $1,914,000. Acadian Asset Management LLC purchased a new stake in Halozyme Therapeutics during the first quarter worth approximately $195,000. Intech Investment Management LLC grew its stake in Halozyme Therapeutics by 9.9% during the first quarter. Intech Investment Management LLC now owns 153,199 shares of the biopharmaceutical company’s stock worth $9,776,000 after buying an additional 13,789 shares during the period. Focus Partners Wealth grew its stake in Halozyme Therapeutics by 57.8% during the first quarter. Focus Partners Wealth now owns 120,815 shares of the biopharmaceutical company’s stock worth $7,709,000 after buying an additional 44,260 shares during the period. Finally, Empowered Funds LLC purchased a new stake in Halozyme Therapeutics during the first quarter worth approximately $755,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Trading Down 0.1%

Shares of Halozyme Therapeutics stock opened at $53.92 on Thursday. Halozyme Therapeutics has a 1 year low of $42.01 and a 1 year high of $70.51. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The company has a market capitalization of $6.64 billion, a P/E ratio of 15.72, a PEG ratio of 0.42 and a beta of 1.19. The company’s fifty day moving average is $57.27 and its two-hundred day moving average is $56.22.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.13. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $264.86 million for the quarter, compared to the consensus estimate of $231.21 million. During the same period last year, the firm posted $0.79 EPS. Halozyme Therapeutics’s revenue for the quarter was up 35.2% on a year-over-year basis. Analysts forecast that Halozyme Therapeutics will post 4.73 earnings per share for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.